A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effectiveness and safety of intravenous injection of RC48-ADC in
the treatment of HER2 expression (HER2 positive and HER2 low expression) gynecological
malignancies.